Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a significant advancement for obesity treatment. Early patient trials have demonstrated impressive losses in visceral fat , potentially exceeding current body composition treatments. However , additional ass